Go Pro
→ Buy this stock today (From Chaikin Analytics) (Ad)tc pixel Free GLSI Stock Alerts

Greenwich LifeSciences (GLSI) Financials

Greenwich LifeSciences logo
$19.57 +0.70 (+3.71%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$20.00 +0.43 (+2.20%)
As of 07/9/2026 07:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Greenwich LifeSciences

Annual Income Statements for Greenwich LifeSciences

This table shows Greenwich LifeSciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -3.43 -1.86 -4.57 -7.83 -8.89 -17 -19
Consolidated Net Income / (Loss)		 -3.43 -1.86 -4.57 -7.83 -8.89 -17 -19
Net Income / (Loss) Continuing Operations		 -3.43 -1.86 -4.57 -7.83 -8.89 -17 -19
Total Pre-Tax Income 		-3.43 -1.86 -4.57 -7.83 -8.89 -17 -19
Total Operating Income		 -3.43 -1.86 -4.60 -8.04 -9.33 -18 -19
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 3.43 1.86 4.60 8.04 9.33 18 19
Selling, General & Admin Expense		 0.82 0.81 1.04 1.56 1.63 2.16 2.23
Research & Development Expense		 2.61 1.06 3.56 6.48 7.70 15 17
Total Other Income / (Expense), net		 0.00 0.00 0.03 0.22 0.44 0.22 0.09
Interest & Investment Income		 0.00 0.00 0.03 0.22 0.44 0.22 0.09
Basic Earnings per Share		 ($1.52) ($0.20) ($0.35) ($0.61) ($0.69) ($1.34) ($1.43)
Weighted Average Basic Shares Outstanding		 2.26M 9.50M 12.94M 12.91M 12.85M 13.01M 13.53M
Diluted Earnings per Share		 ($1.52) ($0.20) - ($0.61) ($0.69) ($1.34) ($1.43)
Weighted Average Diluted Shares Outstanding		 2.26M 9.50M 12.94M 12.91M 12.85M 13.01M 13.53M

Quarterly Income Statements for Greenwich LifeSciences

This table shows Greenwich LifeSciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -2.39 -2.75 -2.47 -2.61 -2.67 -8.04 -2.74 -4.03 -4.15 -7.92 -5.66
Consolidated Net Income / (Loss)		 -2.39 -2.75 -2.47 -2.61 -2.67 -8.04 -2.74 -4.03 -4.15 -7.92 -5.66
Net Income / (Loss) Continuing Operations		 -2.39 -2.75 -2.47 -2.61 -2.67 -8.04 -2.74 -4.03 -4.15 -7.92 -5.66
Total Pre-Tax Income 		-2.39 -2.75 -2.47 -2.61 -2.67 -8.04 -2.74 -4.03 -4.15 -7.92 -5.66
Total Operating Income		 -2.50 -2.84 -2.54 -2.66 -2.73 -8.08 -2.77 -4.05 -4.17 -7.94 -5.73
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Operating Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 2.50 2.84 2.54 2.66 2.73 8.08 2.77 4.05 4.17 7.94 5.73
Selling, General & Admin Expense		 0.34 0.50 0.34 0.35 0.44 1.93 0.50 0.54 0.65 0.36 0.52
Research & Development Expense		 2.16 2.33 2.19 2.31 2.29 6.16 2.27 3.51 3.52 7.59 5.21
Total Other Income / (Expense), net		 0.11 0.09 0.06 0.05 0.06 0.04 0.02 0.02 0.02 0.02 0.07
Interest & Investment Income		 0.11 0.09 0.06 0.05 0.06 0.04 0.02 0.02 0.02 0.02 0.07
Basic Earnings per Share		 ($0.19) ($0.20) ($0.19) ($0.20) ($0.20) ($0.62) ($0.21) ($0.30) ($0.30) ($0.58) ($0.39)
Weighted Average Basic Shares Outstanding		 12.85M 12.85M 12.86M 12.91M 13.14M 13.01M 13.17M 13.37M 13.64M 13.53M 14.57M
Diluted Earnings per Share		 ($0.19) ($0.20) ($0.19) ($0.20) ($0.20) ($0.62) ($0.21) ($0.30) ($0.30) ($0.58) ($0.39)
Weighted Average Diluted Shares Outstanding		 12.85M 12.85M 12.86M 12.91M 13.14M 13.01M 13.17M 13.37M 13.64M 13.53M 14.57M
Weighted Average Basic & Diluted Shares Outstanding		 12.85M 0.00 12.88M 13.14M 13.14M 0.00 13.37M 13.63M 13.85M 0.00 14.68M

Annual Cash Flow Statements for Greenwich LifeSciences

This table details how cash moves in and out of Greenwich LifeSciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.08 29 -1.46 -14 -6.48 -2.90 2.09
Net Cash From Operating Activities		 -0.29 -1.15 -4.29 -6.20 -6.48 -7.27 -9.91
Net Cash From Continuing Operating Activities		 -0.29 -1.15 -4.29 -6.20 -6.48 -7.27 -9.91
Net Income / (Loss) Continuing Operations		 -3.43 -1.86 -4.57 -7.83 -8.89 -17 -19
Consolidated Net Income / (Loss)		 -3.43 -1.86 -4.57 -7.83 -8.89 -17 -19
Amortization Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 2.69 0.68 0.66 1.74 2.38 7.25 6.80
Changes in Operating Assets and Liabilities, net		 0.43 0.03 -0.39 -0.12 0.03 2.89 2.64
Net Cash From Investing Activities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash From Continuing Investing Activities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash From Financing Activities		 0.22 30 2.84 -7.54 0.00 4.37 12
Net Cash From Continuing Financing Activities		 0.22 30 2.84 -7.54 0.00 4.37 12
Issuance of Common Equity		 0.00 30 3.11 - 0.00 4.37 12
Other Financing Activities, net		 - - - - - 0.00 0.15

Quarterly Cash Flow Statements for Greenwich LifeSciences

This table details how cash moves in and out of Greenwich LifeSciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -1.80 -2.15 -1.48 1.72 -1.40 -1.73 -1.34 0.38 0.68 2.37 4.33
Net Cash From Operating Activities		 -1.80 -2.15 -1.78 -1.05 -2.58 -1.85 -1.83 -2.23 -2.67 -3.17 -4.70
Net Cash From Continuing Operating Activities		 -1.80 -2.15 -1.78 -1.05 -2.58 -1.85 -1.83 -2.23 -2.67 -3.17 -4.70
Net Income / (Loss) Continuing Operations		 -2.39 -2.75 -2.47 -2.61 -2.67 -8.04 -2.74 -4.03 -4.15 -7.92 -5.66
Consolidated Net Income / (Loss)		 -2.39 -2.75 -2.47 -2.61 -2.67 -8.04 -2.74 -4.03 -4.15 -7.92 -5.66
Amortization Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - - 0.00
Non-Cash Adjustments To Reconcile Net Income		 0.59 0.59 0.59 0.59 0.59 5.47 1.54 1.54 1.54 2.17 1.54
Changes in Operating Assets and Liabilities, net		 -0.00 -0.00 0.10 0.96 -0.51 0.72 -0.63 0.25 -0.06 2.58 -0.59
Net Cash From Investing Activities		 - - 0.00 - - - 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 - - 0.00 - - - 0.00 - - - 0.00
Net Cash From Financing Activities		 - - 0.30 2.77 1.18 0.12 0.49 2.61 3.35 5.55 9.03
Net Cash From Continuing Financing Activities		 - - 0.30 2.77 1.18 0.12 0.49 2.61 3.35 5.55 9.03
Issuance of Common Equity		 - - 0.30 2.77 1.18 0.12 0.49 2.61 3.21 5.55 9.03

Annual Balance Sheets for Greenwich LifeSciences

This table presents Greenwich LifeSciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.03 29 27 13 6.99 4.09 6.18
Total Current Assets		 0.01 29 27 13 6.99 4.09 6.18
Cash & Equivalents		 0.01 29 27 13 6.99 4.09 6.18
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.02 0.02 0.01 0.01 0.01 0.00 0.00
Total Liabilities & Shareholders' Equity		 0.03 29 27 13 6.99 4.09 6.18
Total Liabilities		 1.38 1.05 0.39 0.26 0.29 3.19 5.82
Total Current Liabilities		 1.38 1.05 0.39 0.26 0.29 3.19 5.82
Accounts Payable		 1.37 0.99 0.22 0.22 0.26 2.80 4.87
Current Deferred Revenue		 - - - - 0.00 0.31 0.67
Current Employee Benefit Liabilities		 0.01 0.06 0.16 0.04 0.04 0.08 0.28
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -1.35 28 27 13 6.70 0.91 0.35
Total Preferred & Common Equity		 -1.35 28 27 13 6.70 0.91 0.35
Total Common Equity		 -1.35 28 27 13 6.70 0.91 0.35
Common Stock		 26 57 60 55 57 69 87
Retained Earnings		 -27 -29 -34 -41 -50 -68 -87

Quarterly Balance Sheets for Greenwich LifeSciences

This table presents Greenwich LifeSciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 9.15 5.51 7.23 5.83 2.75 3.13 3.81 11
Total Current Assets		 9.14 5.51 7.22 5.82 2.75 3.13 3.81 11
Cash & Equivalents		 9.14 5.51 7.22 5.82 2.75 3.13 3.81 11
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity		 9.15 5.51 7.23 5.83 2.75 3.13 3.81 11
Total Liabilities		 0.30 0.39 1.35 0.84 1.44 1.69 1.62 5.24
Total Current Liabilities		 0.30 0.39 1.35 0.84 1.44 1.69 1.62 5.24
Accounts Payable		 0.23 0.35 1.34 0.77 1.05 1.30 1.11 4.51
Current Deferred Revenue		 - - - - 0.31 0.31 - 0.67
Current Employee Benefit Liabilities		 0.07 0.04 0.02 0.07 0.08 0.08 0.51 0.05
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 8.85 5.12 5.88 4.98 1.31 1.44 2.18 5.27
Total Preferred & Common Equity		 8.85 5.12 5.88 4.98 1.31 1.44 2.18 5.27
Total Common Equity		 8.85 5.12 5.88 4.98 1.31 1.44 2.18 5.27
Common Stock		 56 58 61 63 71 75 80 98
Retained Earnings		 -48 -53 -55 -58 -69 -73 -78 -93

Annual Metrics And Ratios for Greenwich LifeSciences

This table displays calculated financial ratios and metrics derived from Greenwich LifeSciences' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 12,019,089.00 13,123,377.00 12,848,165.00 12,848,165.00 - 13,854,539.00
DEI Adjusted Shares Outstanding		 0.00 12,019,089.00 13,123,377.00 12,848,165.00 12,848,165.00 - 13,854,539.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -0.16 -0.35 -0.61 -0.69 - -1.40
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% 45.64% -146.98% -74.93% -16.02% -71.68% -10.28%
EBIT Growth		 0.00% 45.59% -146.70% -74.87% -16.01% -71.66% -10.27%
NOPAT Growth		 0.00% 45.59% -146.70% -74.87% -16.01% -71.66% -10.27%
Net Income Growth		 0.00% 45.61% -145.34% -71.21% -13.63% -77.57% -11.16%
EPS Growth		 0.00% 86.84% 0.00% 0.00% -13.11% -75.36% -6.72%
Operating Cash Flow Growth		 0.00% -293.14% -272.22% -44.47% -4.49% -12.16% -36.43%
Free Cash Flow Firm Growth		 0.00% 0.00% -137.36% -48.30% -13.01% -53.04% -16.09%
Invested Capital Growth		 0.00% 24.17% 63.80% 31.85% -13.83% -439.06% -82.98%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -36.37% -6.88% 0.63% -48.77% 0.71%
EBIT Q/Q Growth		 0.00% 0.00% -36.33% -6.88% 0.62% -48.76% 0.71%
NOPAT Q/Q Growth		 0.00% 0.00% -36.33% -6.88% 0.62% -48.76% 0.71%
Net Income Q/Q Growth		 0.00% 0.00% -35.99% -5.81% 0.49% -50.44% 0.60%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -53.16% 2.72%
Operating Cash Flow Q/Q Growth		 0.00% -438.35% -34.95% 1.50% 0.24% 3.99% -15.39%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -4.88% 0.20% -42.28% 15.13%
Invested Capital Q/Q Growth		 0.00% 0.00% 15.63% -11.37% 0.68% -85.54% -259.11%
Profitability Metrics		 - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 99.96% 99.40% 97.33% 95.33% 98.61% 99.54%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 253.65% -14.18% -16.78% -39.08% -89.30% -341.95% -3,068.25%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 254.02% -14.18% -16.78% -39.08% -89.30% -341.95% -3,068.25%
Return on Equity Simple (ROE_SIMPLE)		 253.65% -6.74% -17.03% -59.22% -132.71% -623.07% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.40 -1.30 -3.22 -5.63 -6.53 -11 -14
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -15,034.27% -3.90% -4.84% -10.80% -23.09% -82.67% -111.87%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -97.45% -442.31% -3,854.16%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -3.43 -1.86 -4.60 -8.04 -9.33 -16 -19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.42 -1.86 -4.59 -8.04 -9.32 -16 -19
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 15.86 11.90 14.78 20.17 58.25 824.09
Price to Tangible Book Value (P/TBV)		 0.00 15.87 11.91 14.79 20.19 58.29 824.09
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.01 -1.09 -1.03 -1.02 -1.03 -1.20 -8.14
Leverage Ratio		 -0.02 1.09 1.03 1.02 1.03 1.20 8.14
Compound Leverage Factor		 -0.02 1.09 1.02 0.99 0.98 1.18 8.10
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 -0.15% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.15% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -1,910.81 251.08 496.27 440.59 262.13 22.00 -0.08
Noncontrolling Interest Sharing Ratio		 -0.15% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.01 27.41 70.63 51.23 23.74 2.62 1.06
Quick Ratio		 0.01 27.41 70.63 51.23 23.74 2.62 1.06
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -1.63 -3.88 -5.75 -6.49 -9.94 -11
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -1.36 -1.03 -0.37 -0.25 -0.29 -1.56 -5.82
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.33 0.66 0.12 -0.04 -1.27 -2.64
Enterprise Value (EV)		 7.25 410 292 182 128 144 285
Market Capitalization		 7.25 438 319 195 135 148 291
Book Value per Share		 ($0.60) $2.30 $2.04 $1.03 $0.52 $0.19 $0.03
Tangible Book Value per Share		 ($0.61) $2.30 $2.04 $1.03 $0.52 $0.19 $0.03
Total Capital		 -1.35 28 27 13 6.70 2.53 0.35
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -0.01 -29 -27 -13 -6.99 -4.09 -6.18
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.38 -1.05 -0.39 -0.26 -0.29 -1.56 -5.82
Debt-free Net Working Capital (DFNWC)		 -1.37 28 27 13 6.70 2.53 0.35
Net Working Capital (NWC)		 -1.37 28 27 13 6.70 2.53 0.35
Net Nonoperating Expense (NNE)		 1.03 0.56 1.35 2.20 2.36 4.58 5.74
Net Nonoperating Obligations (NNO)		 -0.01 -29 -27 -13 -6.99 -4.09 -6.18
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.20) ($0.35) ($0.61) ($0.69) ($1.21) ($1.43)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 12.85M 12.95M 12.91M 12.85M 13.01M 13.53M
Adjusted Diluted Earnings per Share		 $0.00 ($0.20) ($0.35) $0.00 ($0.69) ($1.21) ($1.43)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 12.85M 12.95M 12.85M 12.85M 13.01M 13.53M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.20) ($0.35) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 9.50M 12.94M 12.85M 0.00 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -2.40 -1.30 -3.22 -5.63 -6.53 -11 -14
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -96.31% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Greenwich LifeSciences

This table displays calculated financial ratios and metrics derived from Greenwich LifeSciences' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 12,848,165.00 12,848,165.00 12,848,165.00 12,879,995.00 13,144,653.00 - 13,144,653.00 13,368,304.00 13,630,257.00 13,854,539.00 13,854,539.00
DEI Adjusted Shares Outstanding		 12,848,165.00 12,848,165.00 12,848,165.00 12,879,995.00 13,144,653.00 - 13,144,653.00 13,368,304.00 13,630,257.00 13,854,539.00 13,854,539.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.19 -0.21 -0.19 -0.20 -0.20 - -0.21 -0.30 -0.30 -0.57 -0.41
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -5.03% 2.03% -13.22% -52.30% -9.04% -185.11% -9.13% -52.04% -53.02% 18.17% -106.87%
EBIT Growth		 -5.03% 2.03% -13.21% -52.27% -9.03% -185.05% -9.13% -52.02% -52.97% 18.17% -106.80%
NOPAT Growth		 -5.03% 2.03% -13.21% -52.27% -9.03% -185.05% -9.13% -52.02% -52.97% 18.17% -106.80%
Net Income Growth		 -3.14% 1.57% -16.39% -60.08% -11.58% -192.72% -10.98% -54.42% -55.57% 18.03% -106.11%
EPS Growth		 -5.56% 0.00% -11.76% -53.85% -5.26% -210.00% -10.53% -50.00% -50.00% 22.67% -85.71%
Operating Cash Flow Growth		 -16.18% 0.73% -14.50% -8.36% -43.50% 14.02% -2.91% -113.11% -3.38% -71.40% -156.34%
Free Cash Flow Firm Growth		 10.24% 9.08% -3.03% 29.59% 19.38% -125.11% 45.28% -208.95% -57.16% 25.17% 76.24%
Invested Capital Growth		 -27.64% -13.83% -69.30% -358.45% -188.56% -439.06% -273.30% -24.91% -93.16% -82.98% -264.15%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -43.22% -13.31% 10.54% -4.90% -2.54% -196.29% 71.49% -23.27% -3.20% -90.32% 27.93%
EBIT Q/Q Growth		 -43.20% -13.31% 10.54% -4.90% -2.54% -196.23% 71.48% -23.26% -3.18% -90.32% 27.93%
NOPAT Q/Q Growth		 -43.20% -13.31% 10.54% -4.90% -2.54% -196.23% 71.48% -23.26% -3.18% -90.32% 27.93%
Net Income Q/Q Growth		 -46.88% -14.84% 9.96% -5.40% -2.38% -201.28% 71.60% -23.54% -3.14% -90.82% 28.60%
EPS Q/Q Growth		 -46.15% -5.26% 5.00% -5.26% 0.00% -210.00% 72.00% -20.00% 0.00% -93.33% 32.76%
Operating Cash Flow Q/Q Growth		 -86.21% -19.64% 17.25% 41.22% -146.60% 28.32% 0.96% -21.73% -19.62% -18.85% -48.13%
Free Cash Flow Firm Q/Q Growth		 -47.20% -15.46% 17.01% 50.08% -68.54% -222.41% 77.31% -100.46% 14.26% -36.45% 92.79%
Invested Capital Q/Q Growth		 1.14% 0.68% -33.25% -250.39% 37.77% -85.54% 54.84% -17.25% 3.77% -259.11% 10.12%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 95.56% 96.85% 97.48% 97.94% 97.79% 99.46% 99.13% 99.49% 99.45% 99.72% 98.80%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -73.66% -89.30% -109.97% -123.67% -151.72% -341.95% -549.83% -491.94% -543.43% -3,068.25% -676.66%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -73.66% -89.30% -109.97% -123.67% -151.72% -341.95% -549.83% -491.94% -543.43% -3,068.25% -676.66%
Return on Equity Simple (ROE_SIMPLE)		 -100.94% 0.00% -180.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.75 -1.99 -1.78 -1.86 -1.91 -5.66 -1.94 -2.83 -2.92 -5.56 -4.01
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.16% -7.44% -8.01% -8.19% -10.13% -42.98% -19.54% -23.06% -25.54% -45.98% -24.88%
Return On Investment Capital (ROIC_SIMPLE)		 - -29.63% -34.68% -31.71% -38.34% -223.32% -147.69% -196.75% -133.74% -1,574.53% -76.05%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -2.50 -2.84 -2.54 -2.66 -2.73 -8.08 -2.77 -4.05 -4.17 -7.94 -5.73
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.50 -2.84 -2.54 -2.66 -2.73 -8.08 -2.77 -4.05 -4.17 -7.94 -5.73
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 12.83 20.17 50.03 37.84 37.91 58.25 95.56 84.23 62.07 824.09 63.14
Price to Tangible Book Value (P/TBV)		 12.84 20.19 50.07 37.86 37.93 58.29 95.62 84.23 62.07 824.09 63.14
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.03 -1.04 -1.10 -1.08 -1.20 -1.28 -1.41 -1.34 -8.14 -2.01
Leverage Ratio		 1.02 1.03 1.04 1.10 1.08 1.20 1.28 1.42 1.34 8.14 2.01
Compound Leverage Factor		 0.98 1.00 1.01 1.08 1.06 1.19 1.27 1.41 1.34 8.12 1.99
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 222.20 265.19 380.71 87.60 120.05 28.39 14.23 6.54 18.71 6.06 24.58
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 30.76 23.74 14.13 5.34 6.91 2.62 1.91 1.85 2.35 1.06 2.01
Quick Ratio		 30.76 23.74 14.13 5.34 6.91 2.62 1.91 1.85 2.35 1.06 2.01
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.69 -1.95 -1.62 -0.81 -1.36 -4.39 -0.89 -2.50 -2.14 -2.92 -0.21
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.29 -0.29 -0.39 -1.35 -0.84 -1.56 -1.44 -1.69 -1.62 -5.82 -5.24
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.06 -0.04 -0.16 -1.06 -0.55 -1.27 -1.05 -0.34 -0.78 -2.64 -3.80
Enterprise Value (EV)		 104 128 251 215 183 144 123 118 132 285 322
Market Capitalization		 114 135 256 222 189 148 125 121 136 291 333
Book Value per Share		 $0.69 $0.52 $0.40 $0.46 $0.38 $0.19 $0.10 $0.11 $0.16 $0.03 $0.38
Tangible Book Value per Share		 $0.69 $0.52 $0.40 $0.46 $0.38 $0.19 $0.10 $0.11 $0.16 $0.03 $0.38
Total Capital		 8.85 6.70 5.12 5.88 4.98 2.53 1.31 1.44 2.18 0.35 5.27
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -9.14 -6.99 -5.51 -7.22 -5.82 -4.09 -2.75 -3.13 -3.81 -6.18 -11
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.30 -0.29 -0.39 -1.35 -0.84 -1.56 -1.44 -1.69 -1.62 -5.82 -5.24
Debt-free Net Working Capital (DFNWC)		 8.85 6.70 5.12 5.87 4.98 2.53 1.31 1.44 2.18 0.35 5.27
Net Working Capital (NWC)		 8.85 6.70 5.12 5.87 4.98 2.53 1.31 1.44 2.18 0.35 5.27
Net Nonoperating Expense (NNE)		 0.64 0.76 0.70 0.74 0.76 2.38 0.81 1.19 1.23 2.36 1.65
Net Nonoperating Obligations (NNO)		 -9.14 -6.99 -5.51 -7.22 -5.82 -4.09 -2.75 -3.13 -3.81 -6.18 -11
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.19) ($0.20) ($0.19) ($0.20) ($0.20) ($0.62) ($0.25) ($0.30) ($0.30) ($0.58) ($0.39)
Adjusted Weighted Average Basic Shares Outstanding		 12.85M 12.85M 12.86M 12.91M 13.14M 13.01M 13.17M 13.37M 13.64M 13.53M 14.57M
Adjusted Diluted Earnings per Share		 ($0.19) ($0.20) ($0.19) ($0.20) ($0.20) ($0.62) ($0.25) ($0.30) ($0.30) ($0.58) ($0.39)
Adjusted Weighted Average Diluted Shares Outstanding		 12.85M 12.85M 12.86M 12.91M 13.14M 13.01M 13.17M 13.37M 13.64M 13.53M 14.57M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 12.85M 0.00 12.88M 13.14M 13.14M 0.00 13.37M 13.63M 13.85M 0.00 14.68M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.75 -1.99 -1.78 -1.86 -1.91 -5.66 -1.94 -2.83 -2.92 -5.56 -4.01
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Greenwich LifeSciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Greenwich LifeSciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Greenwich LifeSciences' net income appears to be on an upward trend, with a most recent value of -$19.36 million in 2025, rising from -$3.43 million in 2019. The previous period was -$17.41 million in 2024. Find out what analysts predict for Greenwich LifeSciences in the coming months.

Greenwich LifeSciences' total operating income in 2025 was -$19.45 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $19.45 million

Over the last 6 years, Greenwich LifeSciences' total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

Greenwich LifeSciences' total liabilities were at $5.82 million at the end of 2025, a 82.9% increase from 2024, and a 323.0% increase since 2019.

In the past 6 years, Greenwich LifeSciences' cash and equivalents has ranged from $6.84 thousand in 2019 to $28.66 million in 2020, and is currently $6.18 million as of their latest financial filing in 2025.

Over the last 6 years, Greenwich LifeSciences' book value per share changed from -0.60 in 2019 to 0.03 in 2025, a change of -104.3%.


Related Companies

Financial statements for NASDAQ:GLSI last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Simple Options Trading For Beginners' book at no cost - normally $29.97. It ou...
Profits Run | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
The tiny chipmaker set to supply Musk 5 billion chips
SpaceX and xAI just completed a $1.25 trillion merger - and Musk may no longer need data centers from Microsof...
Brownstone Research | Sponsoredtc pixel
The market’s crashing? … There’s an app for that
During the Great Financial Crisis, one firm accurately predicted 464 of 465 bank failures before they happened...
Weiss Ratings | Sponsoredtc pixel